This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

A combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine has been shown to improve progression-free survival in Hodgkin’s lymphoma. Data on overall survival are needed. New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account